Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has reported Other Accumulated Expenses for 6 consecutive years, with $4.4 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Other Accumulated Expenses fell 91.75% year-over-year to $4.4 million; the TTM figure through Dec 2022 stood at $4.4 million (down 91.75% YoY), while the FY2022 annual figure was $4.4 million, down 91.75% from the prior year.
• Other Accumulated Expenses eased to $4.4 million in Q4 2022 per DNLI's latest filing, from $53.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $53.2 million in Q4 2021 and bottomed at $47000.0 in Q2 2018.
• Historically, Other Accumulated Expenses has averaged $14.1 million across 5 years, with a median of $3.5 million in 2019.
• Annual changes were most pronounced in 2018 — Other Accumulated Expenses soared 30801.59% — and 2022, when it slumped 91.75%.
• Denali Therapeutics' Other Accumulated Expenses stood at $19.5 million in 2018, then grew by 23.36% to $24.0 million in 2019, then surged by 96.31% to $47.1 million in 2020, then grew by 12.77% to $53.2 million in 2021, then plunged by 91.75% to $4.4 million in 2022.
• Business Quant data shows DNLI's Other Accumulated Expenses at $4.4 million in Q4 2022, $53.2 million in Q4 2021, and $47.1 million in Q4 2020.